Glatiramer acetate (GA) does not protect from acute brain ischemia/reperfusion injury. (A) (Left panel) Representative 2,3,5-triphenyltetrazolium chloride stains of 3 corresponding coronal brain sections of a GA-treated mouse and a vehicle-treated mouse sacrificed on day 1 after transient middle cerebral artery occlusion (tMCAO). GA was applied 30 min before tMCAO at a dosage of 3.5 mg/kg bodyweight. Stroke sizes appeared to be similar between the two groups and this was confirmed by infarct volumetry (right panel) (n = 7/group). (B) GA did not improve functional outcome on day 1 after tMCAO. The Bederosn score (left panel) and the grip test (right panel) did not differ between GA-treated mice and vehicle-treated controls (n = 5-7/group). Unpaired, 2-tailed Student’s t test (infarct volumes) or Mann–Whitney Test (Bederson score, grip test); n.s. = not significant.